Antibody discovery

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Anton  Simeonov
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2022
Award: $146,225
Funding agency: National Center for Advancing Translational Sciences

The antibody discovery project harnesses the therapeutic potential of small biologicals known as nanobodies. By constructing a humanized llama phage display library for use here at NCATS, it is possible to screen for therapeutically relevant nanobodies as needed. The small size of nanobodies makes them ideal for binding inside protein folds and clefts that are generally inaccessible to conventional antibodies. This allows NCATS to pursue avenues of therapeutic development that have not yet been explored. Recent work includes identifying binders against the SARS-CoV-2 RBD were identified that could decrease viral cell entry. Through NIH collaborations, the binding of these nanobodies to the SARS-CoV-2 spike trimer domains were imaged by CryoEM. This research has been published and patent has been filed to protect the library. Additionally, a collaboration with NCI involved screening for modulators of CD206 that could trigger reprograming in tumor associated macrophages is underway.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Antibodies><Binding><COVID-19 virus><COVID19 virus><Cell Body><Cells><CoV-2><CoV2><Collaborations><Cryo-electron Microscopy><Cryoelectron Microscopy><Electron Cryomicroscopy><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GPCR><Goals><Image><Legal patent><Libraries><Llama><Methods><Molecular Interaction><NCATS><NIH><National Center for Advancing Translational Sciences><National Institutes of Health><Patents><Patients><Phage Display><Production><Proteins><Publishing><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Therapeutic><Tumor-associated macrophages><United States National Institutes of Health><Viral><Work><Wuhan coronavirus><base><coronavirus disease 2019 virus><coronavirus disease-19 virus><cryo-EM><cryoEM><hCoV19><imaging><nCoV2><nanobodies><nanobody><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel therapeutics><novel therapy><programs><protein folding><screening><sdAb><single domain antibodies><therapeutic agent development><therapeutic development>